Open AccessPharmacologic and psychological interventions for depression treatment in patients with kidney disease
Author(s) -
L. Parker Gregg,
S. Susan Hedayati
Publication year - 2020
Publication title -
current opinion in nephrology and hypertension/current opinion in nephrology and hypertension, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.158
H-Index - 95
eISSN - 1080-8221
pISSN - 1062-4821
DOI - 10.1097/mnh.0000000000000629
Subject(s) - sertraline , tolerability , kidney disease , medicine , antidepressant , depression (economics) , adverse effect , placebo , serotonin reuptake inhibitor , clinical trial , cognitive behavioral therapy , psychiatry , randomized controlled trial , alternative medicine , pathology , macroeconomics , hippocampus , economics
It remains controversial whether existing therapies, including pharmacologic and psychological interventions, are effective for treatment of depression in patients with chronic kidney disease (CKD) and end-stage kidney disease.